Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 19 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research

Catalyst Screening

Enzyme Catalysis

Medicinal Chemistry

Synthetic Chemistry

Analytical Chemistry

Full Time Equivalent(FTE)

Fee For Service(FFS)

Biology Research

Structural Biology

Cell Biology

Enzymology & Molecular Interactions

Antibody Discovery

Translational Medicine

Computational Biology & Molecular Modeling

Early Pharmacokinetics

Radiolabel ADME

02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients

Route Selection

Production Process Optimization

Clinical Sample Production

Impurity Traceability & Control

Generic Drug Process Study & Filing

Innovative Drug Process Study & Filing

Pharmaceutical preparation

Consistency Evaluation

Preformulation Study

Formulation Stability Study

GMP-based Clinical Sample Production & Packaging

Pilot-scale Preparation Testing

Laboratory-scale Preparation Testing

Preparation Quality Research

Formulation Technology Research

Analytical Method Development and Quality Control
CMC Filings
03 Preclinical Research
Pharmacology & Pharmacodynamics

Tumor Models

Digestive System Disease Models

Endocrine & Metabolic Disease Models

Inflammatory & Immune Diseases Models

Neural System Disease Models

Other Disease Models

Ocular Diseases Models

Cardiovascular Model

Drug Safety Evaluation

Pharmacology & Toxicology Study

Safety Pharmacology

Histopathological Study

Clinicopathological Study

Drug Safety Evaluation Basic Information

Toxicokinetics

DMPK

In Vitro ADME Assays

In Vivo Pharmacokinetic Assays

Bioanalysis

Macromolecular Drugs Bioanalysis

Micromolecular Drugs Bioanalysis

IND Filings
01 One-stop Integrated Services
Drug Discovery Platform
Pharmaceutical Research Platform
Preclinical Research Services
Chemical Drug Development
One-stop API Process R&D Department
Medicilon's CDMO Service Platform
Pharmaceutical Research CDMO Service Platform
Translational Medicine Platform
GLP-1 New Drug R&D Service
Botanical Drug Preclinical R&D Technology Platform
02 Innovative Drug Services
ADC R&D Service Platform
PROTAC R&D Service Platform
mRNA Vaccine Bioanalysis Platform
Non-clinical Research for Cellular Immunotherapies
Nucleic Acid Drug R&D Platform
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Platform
Metabolite Identification (MetID) Service Platform
Drug Forming Research Platform
Safety Assessment Lab of Process Chemistry
Flow Cytometry Technology Platform
SEND Format Conversion Platform
Process Department Solid Form Screening Platform
Green Chemistry Platform
Flow Sorting Platform
NanoString nCounter Detection Platform
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model Evaluation Platform
Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease Drug Efficacy Evaluation System
05 Advanced Preparation R&D
Inhalation drug R&D platform
Ophthalmic drug R&D platform
Skin Topical Preparation R&D
06 Drug Analysis
07 Public Services
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 50 Soldiers Field Place, Boston, MA 02135 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2023-07-27Medicilon Events
The Medicilon DMPK team was praised again, and Dr. Yan Feng, CEO of Leading Tac Pharma, came to present the award
Dr. Yan Feng, CEO of Leading Tac Pharma, came to present the award the Medicilon DMPK team the "Best Partner Award" to express their gratitude and recognition.
Learn more
2023-07-27Medicilon Events
Fudan University, School of Management "Science and Technology Entrepreneur Camp" entered Medicilon: "Hardcore Technology" as the background color, Adding "luster" to new drug research and development
On July 14, Professor Xiongwen Lu, Dean of the School of Management of Fudan University, led the professor group of Fudan School of Management and the students of the fifth phase of the Fudan Science and Technology Entrepreneur Camp into the Zhangjiang Park of Shanghai Medicilon Inc. (Medicilon) to conduct a site visit.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CAREERS
Talent Development
Employee Activities
Campus Recruitment
Social Recruitment
Campus Recruitment
Campus Recruitment
Social Recruitment
Social Recruitment
Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon FTE services & FFS services - flexible and efficient cooperation model| Medicilon appeared at the 25th SAPA-NE Annual Conference
Feb 18,2022
Medicilon Appoints Dr. Zhenrong Guo as Executive Vice President of VCMC
Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Zhenrong Guo as the Executive Vice President of VCMC(APIs + Preparations).
More
Medicilon Appoints Dr. Zhenrong Guo as Executive Vice President of VCMC
Feb 17,2022
World's First Inhaled Nanobody Drug LQ036
In the development process of the world's first inhaled nanobody drug for the treatment of moderate and severe asthma, Medicilon assists LQ036 to complete the quality research services of inhaled preparations.
More
World's First Inhaled Nanobody Drug LQ036
Jan 27,2022
Happy Chinese New Year!
Happy Chinese New Year!
More
Happy Chinese New Year!
Jan 24,2022
Medicilon Assisted DAC Biotechnology's Fourth ADC Drug DXC007 Getting Approved for Clinical Use
On December 28, 2021, Hangzhou DAC Biotechnology Co., Ltd. (DAC Biotech) DXC007 project was successfully approved for clinical trials. DXC007 is the fourth ADC drug approved for clinical use by DAC Biotech, and it is also the fourth ADC drug that Shanghai Medicilon Inc. (Medicilon) to help DAC Biotech successfully getting approval.
More
Medicilon Assisted DAC Biotechnology's Fourth ADC Drug DXC007 Getting Approved for Clinical Use
Jan 11,2022
Medicilon Assisted Regor Therapeutics Group's New-generation Tumor-targeting Inhibitor RGT-419B Getting Approved for Clinical Use
On December 28, 2021, the new generation of CDK2/4/6 small molecule inhibitor RGT-419B independently developed by Regor Therapeutics Group (Regor) was approved by the U.S. Food and Drug Administration (FDA).
More
Medicilon Assisted Regor Therapeutics Group's New-generation Tumor-targeting Inhibitor RGT-419B Getting Approved for Clinical Use
Jan 10,2022
Bao Pharmaceutical and Medicilon reached a strategic collaboration
On December 17, 2021, Shanghai Bao Pharmaceutical Co., Ltd. (Bao) and Shanghai Medicilon Inc. (Medicilon) signed an innovative drug IND R&D service strategy collaboration agreement.
More
Bao Pharmaceutical and Medicilon reached a strategic collaboration
Jan 04,2022
Recording the Growth of Medicilon in 2021
This year, Medicilon, with persistent belief, courageously and innovatively, pursued quality, and gave birth to the power of joint growth. Today, we take you to review the 2021 and witness the growth and progress of Medicilon!
More
Recording the Growth of Medicilon in 2021
Dec 20,2021
Medicilon won the 2020 "Golden Bull Science and Technology Innovation Award"
On December 20, China Securities Journal announced the list of the 23rd (2020) "Golden Bull Awards" for listed companies. Shanghai Medicilon Inc. (Medicilon) won the 2020 "Golden Bull Science and Technology Innovation Award."
More
Medicilon won the 2020 "Golden Bull Science and Technology Innovation Award"
Nov 24,2021
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project
Recently, the "2021 Yangpu Service Trade Digital Transformation Forum” under the guidance of the Shanghai Municipal Commission of Commerce and the People's Government of Yangpu District was grandly held.
More
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project
Nov 24,2021
Dr. Chunlin Chen was Awarded the 2021 Super CEO of the Pharmaceutical and Health Industry
On November 16, the "2021 Jiemian Health Forum” hosted by Shanghai United Media Group and Jiemian News was successfully held.  As a major part of
More
Dr. Chunlin Chen was Awarded the 2021 Super CEO of the Pharmaceutical and Health Industry
Nov 24,2021
Medicilon is Included in the MSCI China Index!
On the November 12th, the international index compilation company MSCI announced the results of the November quarterly index review.  Shanghai Medicilon Inc. (stock code: 688202.SH)
More
Medicilon is Included in the MSCI China Index!
Nov 22,2021
Within 10 days, three Bispecific Antibody Drugs Assisted by Medicilon were Approved!
On October 19, Bio-Thera's new double-antibody drug BAT7104 was granted implicit approval for clinical trials.
More
Within 10 days, three Bispecific Antibody Drugs Assisted by Medicilon were Approved!
Stock Code
688202

Global

Address: 50 Soldiers Field Place, Boston, MA 02135 (America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 24, Seochojungang-ro 8-gril, Seocho-gu, Seoul, 06643 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->